GS-4182
- Generic Name
- GS-4182
Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated
Phase 2
Recruiting
- Conditions
- HIV-1-infection
- Interventions
- Drug: Bictegravir/emtricitabine/tenofovir alafenamideDrug: GS-1720/GS-4182 FDCDrug: Placebo to Match BVYDrug: Placebo to Match GS1720/GS-4182 FDC
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 675
- Registration Number
- NCT06613685
- Locations
- 🇪🇸
Hospital Clinico San Carlos, Madrid, Spain
🇪🇸Hospital Universitario Virgen de la Victoria, Malaga, Spain
🇵🇷Proyecto ACTU, San Juan, Puerto Rico
Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed
Phase 2
Active, not recruiting
- Conditions
- HIV-1-Infection
- Interventions
- Drug: GS-1720/GS-4182 FDCDrug: Bictegravir/emtricitabine/tenofovir alafenamideDrug: Placebo to Match BVYDrug: Placebo to Match GS1720/GS-4182 FDC
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 675
- Registration Number
- NCT06544733
- Locations
- 🇺🇸
UAB 1917 Research Clinic, Birmingham, Alabama, United States
🇺🇸Pacific Oaks Medical Group, Beverly Hills, California, United States
🇺🇸Be Well Medical Center, Berkley, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath